Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity

Signaling through the receptor for epidermal growth factor receptor (EGFR) is frequently deregulated in solid tumors. Erlotinib (Tarceva, OSI-774, OSI Pharmaceuticals, Inc., Melville, NY) is a low molecular weight, orally bioavailable inhibitor of the EGFR that has been approved for both non–small c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular cancer therapeutics 2006-08, Vol.5 (8), p.2051-2059
Hauptverfasser:	Buck, Elizabeth, Eyzaguirre, Alexandra, Haley, John D, Gibson, Neil W, Cagnoni, Pablo, Iwata, Kenneth K
Format:	Artikel
Sprache:	eng
Schlagworte:	Akt Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - metabolism Cell Line, Tumor Colorectal Neoplasms - drug therapy Colorectal Neoplasms - metabolism Dose-Response Relationship, Drug EGFR erlotinib Erlotinib Hydrochloride HER-3 Humans Lung Neoplasms - drug therapy Lung Neoplasms - metabolism pancreatic Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - metabolism Phosphorylation Protein Kinase Inhibitors - pharmacology Protein Kinases - metabolism Proto-Oncogene Proteins c-akt - drug effects Proto-Oncogene Proteins c-akt - metabolism Quinazolines - pharmacology Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - metabolism Receptor, ErbB-3 - drug effects Receptor, ErbB-3 - metabolism Ribosomal Protein S6 Kinases - drug effects Ribosomal Protein S6 Kinases - metabolism Signal Transduction TOR Serine-Threonine Kinases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!